Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies Inc. (PRX), said the FDA has indicated that it cannot approve the application for Zuplenz at this time, as it has not completed its inspection of the bioequivalence study sites due to an agency-wide restriction on foreign travel to India.
The company's Zuplenz oral soluble film is indicated for the prevention of nausea and vomiting associated with highly- and moderately-emetogenic chemotherapy, radiotherapy and surgery.
In its letter, the FDA advised that they will schedule and perform an inspection of these sites as soon as possible.
Strativa said it will continue to work with the FDA on completing these site inspections and finalization of product labeling. No issues related to the study data or film product were identified, the company added.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.